GeneDx Holdings Corp. (NASDAQ:WGS) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• GeneDx Holdings Corp. has a consensus rating of "Moderate Buy" from eight research firms, with two analysts suggesting a hold and six a buy recommendation.
• The average price target for GeneDx stock among analysts is $104.13, with prices recently adjusted upward by several firms, including Piper Sandler raising it to $140.00.
• Insiders have sold significant amounts of company stock recently, with CEO Katherine Stueland selling over 10,500 shares and a director selling 500,000 shares, indicating a decrease in insider ownership.

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight research firms that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $104.1250.

Several equities analysts recently commented on the stock. Piper Sandler boosted their price objective on shares of GeneDx from $120.00 to $140.00 and gave the company an "overweight" rating in a research note on Thursday, September 11th. Guggenheim reaffirmed a "buy" rating and set a $115.00 price objective (up previously from $88.00) on shares of GeneDx in a research note on Monday, June 30th. Wells Fargo & Company boosted their price target on shares of GeneDx from $78.00 to $95.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 30th. Finally, Wall Street Zen upgraded shares of GeneDx from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd.

Insiders Place Their Bets

In other news, CEO Katherine Stueland sold 10,501 shares of the business's stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $121.47, for a total transaction of $1,275,556.47. Following the completion of the transaction, the chief executive officer owned 14,578 shares of the company's stock, valued at approximately $1,770,789.66. The trade was a 41.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Casdin Capital, Llc sold 500,000 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $120.90, for a total transaction of $60,450,000.00. Following the completion of the transaction, the director directly owned 3,007,164 shares of the company's stock, valued at approximately $363,566,127.60. This represents a 14.26% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 564,869 shares of company stock valued at $68,279,628 in the last ninety days. Corporate insiders own 29.60% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its position in GeneDx by 151.7% in the first quarter. GAMMA Investing LLC now owns 438 shares of the company's stock worth $39,000 after acquiring an additional 264 shares in the last quarter. US Bancorp DE boosted its holdings in shares of GeneDx by 3,223.5% in the 1st quarter. US Bancorp DE now owns 565 shares of the company's stock worth $50,000 after purchasing an additional 548 shares in the last quarter. AlphaQuest LLC boosted its holdings in shares of GeneDx by 351.5% in the 2nd quarter. AlphaQuest LLC now owns 763 shares of the company's stock worth $70,000 after purchasing an additional 594 shares in the last quarter. KBC Group NV purchased a new position in shares of GeneDx in the 1st quarter worth about $81,000. Finally, PNC Financial Services Group Inc. purchased a new position in shares of GeneDx in the 1st quarter worth about $132,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

GeneDx Stock Down 5.4%

GeneDx stock opened at $107.74 on Wednesday. The company has a current ratio of 2.87, a quick ratio of 2.70 and a debt-to-equity ratio of 0.19. GeneDx has a 1-year low of $40.40 and a 1-year high of $136.00. The firm has a market capitalization of $3.10 billion, a price-to-earnings ratio of 2,154.80 and a beta of 2.04. The firm has a 50 day simple moving average of $116.72 and a 200 day simple moving average of $93.99.

GeneDx (NASDAQ:WGS - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.10 by $0.40. GeneDx had a return on equity of 16.51% and a net margin of 0.39%.The company had revenue of $102.69 million for the quarter, compared to analyst estimates of $86.00 million. GeneDx has set its FY 2025 guidance at EPS. On average, analysts predict that GeneDx will post 0.97 earnings per share for the current year.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.